GT Biopharma, Inc.
NASDAQ: GTBP0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Michael Martin Breen
- Employees
- 1
- Headquarters
- San Francisco, United States
- IPO year
- 2018
- Market cap
- $4.8M
- Website
- https://www.gtbiopharma.com
Loading GTBP…
Loading profile data…Frequently asked questions about GTBP
What does GT Biopharma, Inc. (GTBP) do?
GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tri-specific Killer Engager (TriKE) fusion proteins, which are designed to harness the body's immune c...
Where does GTBP trade?
GT Biopharma, Inc. (GTBP) trades on the NASDAQ Capital Market.
What sector is GTBP in?
GT Biopharma, Inc. (GTBP) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of GT Biopharma, Inc.?
Michael Martin Breen is the chief executive officer of GT Biopharma, Inc. (GTBP).
Where is GT Biopharma, Inc. headquartered?
GT Biopharma, Inc. is headquartered in United States.
Does GTBP pay a dividend?
GT Biopharma, Inc. (GTBP) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did GTBP go public?
GT Biopharma, Inc. (GTBP) completed its initial public offering in 2018.